Get the latest Science News and Discoveries
Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen - EurekAlert
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak.
None
Or read this on Eureka Alert